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Summary
Haematopoietic stem cell transplantation (HSCT) is a
highly specialised procedure used to treat malignancies of
the lymphohaematopoietic system as well as some acquired
and inherited disorders of the blood. This analysis by the
Swiss Blood Stem Cell Transplantation Group, based on
data from 2008–2011, describes, treatment rates in Switzer-
land for specific indications and compares this with data
from Germany, France, Italy and the Netherlands, corrected
for the size of the population. Differences in transplant
rates, in rates for particular indications, and in the use of
specific transplant technologies such as use of unrelated
donors, use of cord blood or mismatched family donors
are described. These data are put in correlation with donor
availability from international registries and with number
of transplant teams and number of procedures per team all
corrected for population size.
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Introduction
Haematopoietic stem cell transplantation (HSCT) has be-
come an established treatment option for a wide range
of haemato-oncological tumours, some solid tumours, and
nonmalignant diseases such as bone marrow failure,
primary immunodeficiencies and other congenital and ac-
quired disorders [1–2]. The haematopoietic system is re-
placed in the form of haematopoietic stem cells from either
the patients themselves (autologous HSCT) or other per-
sons (allogeneic HSCT). Autologous HSCT is used to
bridge haematopoietic failure during high-dose chemother-
apy for the treatment of tumours of the haematopoietic sys-
tem and some solid tumours that are adequately sensitive
to this treatment. Allogeneic HSCT is used to replace the
haematopoietic system in patients with acquired or congen-
ital haematopoietic failure, and more commonly to exploit
the graft versus tumour effect of allogeneic cells in malig-
nant disease [1–4]. Donors for allogeneic HSCT may come
from the patient's family, or may be unrelated and provided
by donor registries. Furthermore, cryopreserved cord blood
has become an accepted stem cell source [5–7] for certain
indications.
Before HSCT, chemotherapy or chemotherapy in combin-
ation with total body irradiation is administered. The goal
of these conditioning regimens in autologous HSCT is to
administer cytotoxic chemotherapy to the tumour, without
any compromises in intensity because of marrow toxicity,
but to preserve nonhaematopoietic organ function. HSCT
serves to restore bone marrow function and to shorten
aplasia. Historically, in allogeneic HSCT marrow-ablative
doses of chemotherapy and total-body irradiation were
thought to be necessary to eradicate malignancy, to provide
immunosuppression in the recipient, and to create space in
the stem cell compartment, allowing engraftment of donor
haematopoietic cells. A major development over the last 15
years was the introduction of reduced intensity regimens
(reduced intensity conditioning; RIC), in which myeloab-
lative treatment is avoided and treatment intensity is just
high enough to avoid graft rejection [8]. The goal was to
promote engraftment and let the graft versus tumour effect
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eliminate tumour cells. The reduction in toxicity with RIC
results in less morbidity and mortality, and has made allo-
geneic HSCT available to patients with comorbidities and
to older patients (i.e., patients aged 60 to 70 years, the age
group that has the highest prevalence of most haematopoi-
etic malignancies).
Health technology assessment is used to identify appro-
priate treatment and use of medical technology in HSCT.
Costs for these technologies are high and indications are
therefore scrutinised for their appropriateness in a given
patient population. Use of HSCT technology may vary be-
cause of socioeconomic conditions determining access, or
because of reimbursement issues [9–11], but the number
of studies analysing appropriateness of technology use are
limited [12, 13]. It was the purpose of this study to compare
indications for, and use of, transplant technology in
Switzerland with those of neighbouring countries. As these
countries are all in a more or less comparable economic
situation, and as incidences of haematological malignan-
cies are not expected to differ greatly between them, differ-
ences in transplant rates require explanation. No outcome
data are provided.
Figure 1
Allogeneic HSCT rates per 10 million inhabitants per year. 1a: all
allogeneic HSCT. 1b: allogeneic HSCT from a family donor. 1c:
allogeneic HSCT from an unrelated donor (CH: Switzerland, F:
France, D: Germany, I: Italy, NL: the Netherlands)
Patients and methods
The data for this analysis were taken from the Activity Sur-
vey of the European Group for Blood and Marrow Trans-
plantation (EBMT) [14–16]. In brief, teams are requested
to report data annually by indication, stem cell source and
donor type. Quality control measures include several in-
dependent systems: confirmation of validity of the entered
data by the reporting team, selective comparison of the sur-
vey data with data sets in the EBMT Registry database,
cross-checking with the National Registries, and onsite vis-
its of selected teams. In addition, data for Switzerland are
validated by the referring teams when they prepare the an-
nual reports for the Federal Office of Public Health under
the Swiss Transplant Law.
For the purpose of this study, data from Switzerland were
compared with three neighbouring countries, Germany,
France and Italy, and also with the Netherlands, all coun-
tries with somewhat differing healthcare systems. Data
from 304 centres from the five countries were obtained for
the years 2008–2011 and averaged over the 4 years.
Data on registered unrelated donors were obtained from
the national registries and crosschecked with bone marrow
donors worldwide (BMDW).
Wherever appropriate, patient numbers corresponding to
the number of patients receiving a first transplant, and
transplant numbers reflecting the total number of trans-
plants performed, are listed. Situations in which a patient
could receive more than one transplant include multiple
transplants, defined as subsequent transplants within a
planned double or triple autologous or allogeneic transplant
protocol, and retransplants (autologous or allogeneic)
defined as unplanned HSCT for rejection or relapse after a
previous HSCT.
Stem cell sources include bone marrow, peripheral blood
or cord blood. Myeloablative conditioning usually causes
a prolonged state of marrow aplasia and autologous recov-
ery is, if at all, very late and incomplete. Reduced intens-
ity conditioning (RIC) is immunosuppressive to allow en-
graftment but usually causes only a short period of marrow
aplasia or, with some regimens, no aplasia at all.
Transplant rates, defined as numbers of HSCT per 10 mil-
lion inhabitants, were computed for each country. Popula-
tion numbers (in 2011) were obtained from the US census
Figure 2
Number of registered unrelated donors in the national registries of
the five countries studied corrected for population size, presented
as donors per 10 million inhabitants(CH: Switzerland, F: France, D:
Germany, I: Italy, NL: the Netherlands).
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bureau database (http://www.census.gov/population/inter-
national/data/idb/rank.php).
To calculate transplant rates the numbers of first transplants
were used; this reflects the number of patients transplanted
rather than the total number of transplants. For certain
graphs depicting transplant technology, such as percentage
of transplants with RIC, the total numbers of transplants
(including double transplants) were used. Where appropri-
ate, transplant rates are given with the 95% confidence in-
terval, represented by an error bar. there was no formal
statistical comparison because of the descriptive nature of
these observations.
Results
Altogether, 304 teams from the five neighbouring countries
reported a total of 57,933 patients receiving their first trans-
plant during 2008–2011: 24,092 (42%) allogeneic and
33,841 (58%) autologous HSCT. The total number of trans-
plants reported was 66,732: 26,161 allogeneic and 40,571
autologous HSCT. This includes patients who received
more than one transplant through planned procedures such
as double autologous HSCT (e.g., in patients with myel-
Figure 3
Allogeneic HSCT rates per 10 million inhabitants per year. 1a:
leukaemia. 1b: lymphoma. 1c: bone marrow failures syndromes
(CH: Switzerland, F: France, D: Germany, I: Italy, NL: the
Netherlands).
oma) or second transplants after relapse of the original dis-
ease.
The main indications included acute and chronic leukaemia
(16,265 allogeneic; 1,419 autologous), lymphoid malig-
nancies (5,480 allogeneic; 29,031 autologous), solid tu-
mours (187 allogeneic; 3,168 autologous), bone marrow
failure syndromes (869 allogeneic), other nonmalignant
diseases including many different inherited disorders and
autoimmune diseases (1,161 allogeneic; 184 autologous)
and other nonspecified diseases (130 allogeneic, 39 auto-
logous). More details of the disease classification are
provided in table 1.
Of the allogeneic transplants, 9,753 were performed using
a family donor and 14,339 an unrelated donor. The family
donors were human leukocyte antigen (HLA) identical sib-
lings (n = 8231), twins (n = 72) and HLA mismatched rel-
atives (n = 1,450).
Overall, 5,590 allogeneic transplants were performed using
stem cells collected from the bone marrow (2,948 family;
2,642 unrelated), 16,987 with peripheral blood stem cells
(6720 family; 10,266 unrelated) and 1515 with cord blood
stem cells (84 family; 1,431 unrelated).
A total of 33,841 autologous transplants were performed
using peripheral blood stem cells and 234 with bone mar-
Figure 4
Allogeneic HSCT rates per 10 million inhabitants and year. 4a: use
of cord blood transplants. 4b: use of HLA- mismatched family
donors. 4c: use of reduced intensity conditioning as percentage of
all allogeneic HSCT (CH: Switzerland, F: France, D: Germany, I:
Italy, NL: the Netherlands).
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row stem cells. During the study period only two autolog-
ous cord blood transplants were reported.
Figure 1 shows the rates of allogeneic HSCT in the five
countries, in total (rates of 198–311 per 10 million popu-
lation per year), and separately for unrelated donor HSCT
(106–218 per 10 million population per year) and family
donor HSCT. The rates of HSCT from a family donor vary
little between the countries and are between 89 and 128
per 10 million inhabitants per year. Of interest is the im-
portant difference in the rate of use of unrelated donors for
allogeneic HSCT, which in Germany is double the rate in
Switzerland (218 vs 109 per 10 million population per year).
Figure 2 shows the numbers of donors available in the re-
spective national registries in the five countries, corrected
for population size (donor rates 23,026–456,598 per 10 mil-
lion population per year). The huge differences reflect the
major effort undertaken by German registries to recruit stem
cell donors. Figure 3 shows rates of allogeneic HSCT for
three indications: leukaemias (139–218 per 10 million popu-
lation), lymphoid malignancies (38–70 per 10 million popu-
lation per year) and bone marrow failure (7–12 per 10 milli-
on population per year). For all three indications Switzerland
has the lowest rate of allogeneic HSCT, although some of
the differences are small. Figure 4a shows differences in the
use of cord blood as a stem cell source; there are striking
differences in the use of cord blood for allogeneic HSCT, as
high as 32 per 10 million inhabitants per year in France and
as low as 3 per 10 million inhabitants per year in Germany.
Unrelated cord blood is most commonly used when no HLA
matched unrelated donor is available; other options in such
a situation include using family donors mismatched at mul-
tiple HLA loci (haploidentical donors). Transplant rates with
mismatched family donors (3–31 per 10 million population
per year) are shown in figure 4b. It appears that there is
complementary relationship between use of the two sources:
countries that use cord blood rarely use mismatched family
donors. Conversely transplantation rates from mismatched
family donors are high in Germany (14 per 10 million in-
habitants per year) and Italy (33 per 10 million inhabitants
per year), where use of cord blood is low. Use of RIC as op-
posed to standard intensity conditioning is also variable, as
shown in figure 4c, where percentages of RIC transplants in
the Netherlands (61%) are approximately twice as high as
those in, for example, Italy (29%).
Figure 5 shows rates of autologous HSCT in the European
countries. Differences appear smaller than for allogeneic
HSCT (fig. 5a), especially in the indications that are gen-
erally accepted such as non-Hodgkin’s lymphoma (97–143
per 10 million inhabitants per year; fig. 5c) and myeloma
(139–160 per 10 million inhabitants per year; fig. 5d),
where almost no difference is apparent in transplant rates.
This is very different for other indications, however, as ex-
emplified by autologous HSCT for leukaemia (5–34 per 10
million inhabitants per year; fig. 5b) and Hodgkin’s disease
(18–53 per 10 million inhabitants per year; fig. 5d).
Figures 6 and 7 show team densities (the number of trans-
plant teams per 10 million inhabitants) for allogeneic
HSCT (3.8–10.6) and autologous HSCT (8.7–15.1), and
the number of transplants per team averaged over the 4
years (22–51 allogeneic HSCT per team, 26–41 autologous
HSCT per team). There is an inverse correlation, as the
country with the lowest team density has the highest num-
ber of procedures per team, as exemplified by team density
figures for allogeneic HSCT (3.8 teams per 10 million pop-
ulation) and rates of allogeneic HSCT in Switzerland (51
transplants per team). The fact that Switzerland also has the
lowest overall rate of allogeneic HSCT demonstrates that
the higher number of procedures per team only partially
compensates for the lower team density.
Discussion
This study by the Swiss Blood Stem Cell Transplantation
Group (SBST) describes the use of haematopoietic stem
Figure 5
Autologous HSCT rates per 10 million inhabitants per year. 5a:
autologous HSCT. 5b: leukaemia. 5c: myeloma. 5d: non-Hodgkin’s
lymphoma. 5e: Hodgkin‘s disease (CH: Switzerland, F: France, D:
Germany, I: Italy, NL: the Netherlands).
Figure 6
Transplant team density (number of teams per 10 million
inhabitants). 6a: allogeneic HSCT. 6b: autologous HSCT (CH:
Switzerland, F: France, D: Germany, I: Italy, NL: the Netherlands).
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cell transplantation technology in Switzerland, making use
of the database used to report transplants to the federal gov-
ernment and comparing rates and indications with neigh-
bouring countries. This analysis is based on the accepted
activity surveys of the EBMT, confirming and extending
previous findings. In Switzerland, all transplant centres are
accredited by JACIE (the joint accreditation committee of
ISCT and EBMT; http://www.jacie.org) and through this
Figure 7
Average annual number of allogeneic and autologous HSCT per
transplanting team. 7a: allogeneic HSCT. 7b: autologous HSCT
(CH: Switzerland, F: France, D: Germany, I: Italy, NL: the
Netherlands).
mechanism all transplants are reported. Within the JACIE
accreditation programme, in Switzerland 100% of centres,
in the Netherlands 93%, in France 58%, in Germany 43%
and in Italy 34% of centres, have either registered an ap-
plication for accreditation, are already accredited or are in
the process of being accredited (JACIE annual report 2011;
http://www.jacie.org/about/annual-report).
The activity survey of the EBMT was used for data on
the countries other than Switzerland. Main findings include
lower rates of allogeneic HSCT in Switzerland than in
neighbouring countries. Most of this difference is due to
a higher rate of HSCT from unrelated donors, and the
most striking difference is with Germany where the rate is
double that in Switzerland.
There is published data to explain some of the differences
in HSCT rates. Adoption of HSCT is primarily influenced
by availability of resources, governmental support and ac-
cess to a transplant centre [17]. Use of HSCT is also influ-
enced by the economic situation, medical evidence, extern-
al regulations and expectations [7]. Use of unrelated donors
correlates with resources, availability of an unrelated donor
registry and number of donors in the registry of that coun-
try. Given the wide variation between countries in the size
of unrelated donor registries, it is obvious that additional
efforts in education and recruitment have to be undertaken
in countries such as Switzerland. It is particularly disturb-
ing that the country with the highest GDP in the series ex-
amined has a particularly low rate of donor availability.
As family size does not vary greatly in Europe and the like-
lihood of a given pair of siblings being HLA identical is
25% by the law of Mendelian inheritance, it is not surpris-
ing that rates for allogeneic HSCT using family donors do
not differ greatly among European countries.
Table 1: Absolute numbers of patients transplanted by disease indication and transplant type.
Indication stage Allogeneic HSCT Autologous HSCT Total
Leukaemias 16265 1419 17684
Acute myeloid leukaemia 7896 1133 9029
Acute lymphoblastic leukaemia 3582 217 3799
Chronic myeloid leukaemia 688 5 693
Myelodysplastic syndrome / myeloproliferative neoplasm 4099 64 4163
Lymphoid malignancies 5480 29031 34511
Chronic lymphatic leukaemia 871 140 1011
Plasma cell disorder 1618 14449 16067
Hodgkin’s lymphoma 622 2943 3565
Non-Hodgkin’s lymphoma 2369 11499 13868
Solid tumours 187 3168 3355
Neuroblastoma 82 699 781
Soft tissue 27 102 129
Germ cell tumours 2 785 787
Breast Cancer 11 257 268
Ewing sarcoma 30 422 452
All other solid tumours 35 903 938
Nonmalignant disorders 2030 184 2214
Bone marrow failure 869 0 869
Haemoglobinopathy 449 0 449
Primary Immune deficiency 510 13 523
Inherited metabolic disease 173 8 181
Autoimmune disease 29 163 192
Others 130 39 169
Total first HSCT 24092 33841 57933
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A possible explanation for the huge difference in unrelated
donor transplant rates among the five countries (almost
twice as many are performed in Germany than in the other
countries) lies in donor availability. German registries have
made major efforts to recruit unrelated donors, and al-
though donor searches are conducted internationally it is
conceivable that HLA matched donors are more easily
identified in populations that share the same gene pool as
the patient [18]. Some of the differences in rates of unre-
lated donor HSCT are, however, unexplained as donors are
mutually accessible across registries worldwide.
Indications for allogeneic HSCT do not vary greatly (see
fig. 3), that is, leukaemia, lymphoproliferative neoplasia
and marrow failure syndromes. Areas of uncertainty,
however, include the use of HSCT technology in patients
without a matched donor. This is exemplified by the wide
variation in use of cord blood or mismatched family donors
(see fig. 4). The complementarity indicates that, for ex-
ample, in France cord blood donors are used rather than
mismatched family donors, whereas in Germany this is re-
versed. Such differences are attributed to the lack of clear
guidelines, and local preference in the absence of clear data
[16]. Another area of uncertainty is the use of RIC as op-
posed to standard conditioning. This is evident by the per-
centage of allogeneic HSCT using RIC, which is, for ex-
ample, in Italy half the fraction seen in the Netherlands (fig.
4c).
Similar observations can be made for autologous HSCT,
where overall rates are similar across countries. When ana-
lysing by indication it becomes evident that well-estab-
lished indications such as non-Hodgkin's lymphoma and
myeloma show comparable rates, whereas wide variation
is seen in autologous HSCT for acute leukaemia and for
Hodgkin’s lymphoma.
As well as donor availability and physician preference, use
of technology may also be determined by factors such as
access to care, which may be measured as team density
(i.e., the number of teams performing transplants per 10
million inhabitants). It is of interest to see that the country
with the lowest rate of allogeneic HSCT (Switzerland) is
also the country with the lowest team density in this field.
This is, however, partially compensated by the higher num-
ber of transplants per team, as shown in figure 7. Access
to care is an important topic in healthcare decision making,
and in several countries concentration of highly specialised
technology in few centres is being discussed. Arguments
used are economic, as one large centre will be less expens-
ive than two smaller ones, but also concern treatment qual-
ity, as the assumption is that centres performing more pro-
cedures will have greater clinical experience and, therefore,
better results. For a number of medical procedures it has
been shown that a high caseload is beneficial to outcome
although, for reasons not easily explained, this has not been
confirmed for HSCT [19]. A study has shown, however,
that accreditation by JACIE is associated with better out-
come [20], and accreditation is dependent on a minimum
caseload. Our data show that for allogeneic and autolog-
ous HSCT, fewer centres, while being associated with a
higher caseload per centre, also lead to fewer procedures. It
would be of interest to compare outcome for particular in-
dications, looking at the relationship between team experi-
ence, and treatment quality and outcome [21].
Given the nature of the data presented here, it is not pos-
sible to determine the appropriate rate of allogeneic HSCT.
Overuse and underuse of technology cannot be determined
because of the lack of a clearly defined benchmark. Over-
all, these data show that standardisation in the field of
HSCT is needed, because the wide variations shown here
are mainly unexplained.
It was the task, therefore, of this analysis to describe dif-
ferences and to make them available to the scientific com-
munity for discussion. Quality management systems, and
mandatory data reporting and analysis of data, are to be
promoted and should be considered an integral part of pa-
tient treatment.
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Figures (large format)
Figure 1
Allogeneic HSCT rates per 10 million inhabitants per year. 1a: all allogeneic HSCT. 1b: allogeneic HSCT from a family donor. 1c: allogeneic
HSCT from an unrelated donor (CH: Switzerland, F: France, D: Germany, I: Italy, NL: the Netherlands)
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Figure 2
Number of registered unrelated donors in the national registries of the five countries studied corrected for population size, presented as donors
per 10 million inhabitants(CH: Switzerland, F: France, D: Germany, I: Italy, NL: the Netherlands).
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Figure 3
Allogeneic HSCT rates per 10 million inhabitants per year. 1a: leukaemia. 1b: lymphoma. 1c: bone marrow failures syndromes (CH: Switzerland,
F: France, D: Germany, I: Italy, NL: the Netherlands).
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Figure 4
Allogeneic HSCT rates per 10 million inhabitants and year. 4a: use of cord blood transplants. 4b: use of HLA- mismatched family donors. 4c:
use of reduced intensity conditioning as percentage of all allogeneic HSCT (CH: Switzerland, F: France, D: Germany, I: Italy, NL: the
Netherlands).
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Figure 5
Autologous HSCT rates per 10 million inhabitants per year. 5a: autologous HSCT. 5b: leukaemia. 5c: myeloma. 5d: non-Hodgkin’s lymphoma.
5e: Hodgkin‘s disease (CH: Switzerland, F: France, D: Germany, I: Italy, NL: the Netherlands).
Original article Swiss Med Wkly. 2013;143:w13757
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 12 of 14
Figure 6
Transplant team density (number of teams per 10 million inhabitants). 6a: allogeneic HSCT. 6b: autologous HSCT (CH: Switzerland, F: France,
D: Germany, I: Italy, NL: the Netherlands).
Original article Swiss Med Wkly. 2013;143:w13757
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Figure 7
Average annual number of allogeneic and autologous HSCT per transplanting team. 7a: allogeneic HSCT. 7b: autologous HSCT (CH:
Switzerland, F: France, D: Germany, I: Italy, NL: the Netherlands).
Original article Swiss Med Wkly. 2013;143:w13757
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